Showing posts with label trials. Show all posts
Showing posts with label trials. Show all posts

Friday, September 20, 2013

0 Allergen immunotherapy as a drug: the new deal of grass allergen tablets from clinical trials to current practice







Allergen immunotherapy as a drug: the new deal of grass allergen tablets fromclinical trials to current practice



G. Manzotti, C. Lombardi



Abstract



Currently, sublingual immunotherapy (SLIT) may be performed by a number of allergen extract in different preparations but in a near future only products fulfilling the requirements from the regulatory agencies, that make mandatory a pharmaceutical quality, will be authorized. Indeed, two products with such characteristics are already available for SLIT in grass pollen allergic patients, Grazax® from Alk-Abellò and Oralair® from Stallergenes. The data from registrative trials as well as from postmarketing studies provide evidence of efficacy and safety of such products. This articles reviews the similarities and the differences of Grazax® and Oralair®, both designed as drugs for the treatment of grass pollen allergy with the aim, which is exclusive of allergen immunotherapy, to work on the natural history of allergy and not only on symptoms as rescue medications do. The aim of this paper is to evaluate the available trials with Grazax® and Oralair® in terms of pre-seasonal schedule approach to support their use in clinical practice.Such kind of treatment makes possible a continuous dialogue between clinical investigators and clinical practitioners, and is the only way for scientific progress that puts the patient’s health at the first place.



Keywords



Sublingual allergen-specific immunotherapy, grass tablets


Full Text: PDF 


Monday, September 16, 2013

0 Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials

Open AccessResearch

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials



Harold R Collard, Eric Yow, Luca Richeldi, Kevin J Anstrom and Craig Glazer










For all author emails, please log on.








Respiratory Research 2013, 14:73 doi:10.1186/1465-9921-14-73

Published: 13 July 2013





Abstract (provisional)


Background


Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure.

Methods


Three investigators retrospectively reviewed subjects enrolled in the Sildenafil Trial of Exercise Performance in IPF who experienced a respiratory serious adverse event during the course of the study. Events were classified as definite acute exacerbation, suspected acute exacerbation, or other, according to established criteria.

Results


Thirty-five events were identified. Four were classified as definite acute exacerbation, fourteen as suspected acute exacerbation, and seventeen as other. Definite and suspected acute exacerbations were clinically indistinguishable. Both were most common in the winter and spring months and were associated with a high risk of disease progression and short-term mortality.

Conclusions


In this study one half of respiratory serious adverse events were attributed to definite or suspected acute exacerbations. Suspected acute exacerbations are clinically indistinguishable from definite acute exacerbations and represent clinically meaningful events. Clinical trialists should consider capturing both definite and suspected acute exacerbations as outcome measures.






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.